<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115800</url>
  </required_header>
  <id_info>
    <org_study_id>CEI-2019/04/01</org_study_id>
    <nct_id>NCT04115800</nct_id>
  </id_info>
  <brief_title>Liposomal Sirolimus in Dry Eye Disease</brief_title>
  <official_title>Subconjunctival Treatment of Liposomal Sirolimus as a Treatment for Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Oftalmología Fundación Conde de Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Oftalmología Fundación Conde de Valenciana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dry eye disease is a very frequent pathology that importantly affects the quality of life of&#xD;
      patients; in spite of the common use of eye lubricants to ameliorate symptoms, there is still&#xD;
      a large number of patients who do not present improvement of the disease or they worsen.&#xD;
      Although its etiology is varied, the imbalance of the immune system plays a substantial role&#xD;
      in the development of dry eye disease. Rapamycin or sirolimus is an anti-inflammatory and&#xD;
      immunomodulatory drug that has an enormous potential in ocular surface pathologies such as&#xD;
      dry eye disease. The aim of the present study is to determine the effectiveness and security&#xD;
      of subconjunctival application of a new formulated drug of liposomal sirolimus in patients&#xD;
      with moderate and severe dry eye disease. This is a randomized placebo-controlled double&#xD;
      blind clinical trial. Patients presenting data of moderate or severe dry eye disease will be&#xD;
      randomized into two groups. One group will receive additional to the conventional treatment,&#xD;
      subconjunctival injections of liposomal sirolimus; meanwhile the other group will receive&#xD;
      subconjunctival placebo injections. After intervention the effectiveness and the security of&#xD;
      the liposomal sirolimus will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2019</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Six weeks after intervention</time_frame>
    <description>The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability. The index demonstrates sensitivity and specificity in distinguishing between normal patients and patients with dry eye disease. The OSDI is a valid and reliable instrument for measuring dry eye disease severity (normal, mild to moderate, and sever) and effect on vision -related function.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Liposomal Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subconjunctival liposomal injections in patients with conventional treatments and moderate and severe dry eye disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Sirolimus</intervention_name>
    <description>Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease</description>
    <arm_group_label>Liposomal</arm_group_label>
    <arm_group_label>Liposomal Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with moderate or severe Dry Eye&#xD;
&#xD;
          -  Subjects with OSDI score &gt; 22&#xD;
&#xD;
          -  Subjects with Van Bijsterveld staining score &gt;4&#xD;
&#xD;
          -  Subjects that accept to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with refraction surgery antecedents&#xD;
&#xD;
          -  Subjects with ophthalmic surgery six months previous to the study&#xD;
&#xD;
          -  Subjects with Lagophthalmos&#xD;
&#xD;
          -  Subjects with facial paralysis antecedents&#xD;
&#xD;
          -  Subjects with herpetic keratitis&#xD;
&#xD;
          -  Subjects using isotretinoin&#xD;
&#xD;
          -  Pregnant subjects&#xD;
&#xD;
          -  Subjects in lactating period&#xD;
&#xD;
          -  Subjects with allergy or intolerant to the drug&#xD;
&#xD;
          -  Subjects with hepatic disorders&#xD;
&#xD;
          -  Subjects with abnormal thoracic X rays&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Oftalmología</name>
      <address>
        <city>Mexico City</city>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Liposomal</keyword>
  <keyword>Subconjunctival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

